Novo Nordisk’s repurchase programme accumulated 17,275,000 B shares worth DKK 5,221,774,293, while total Buybacks since 4 February reached 32,034,179 shares worth DKK 9,021,774,283. The purchases left 46,074,876 B shares in treasury, equal to 1.0% of share capital.
Key Highlights
- Novo Nordisk repurchased 32,034,179 B shares since 4 February 2026 at an average DKK 281.63 per share.
- The company plans purchases of up to DKK 11,200,000,010.45 through 1 February 2027.
- Since 4 February 2026, the company has repurchased 32,034,179 B shares for DKK 9,021,774,283.
- The current programme allows repurchases of up to DKK 11,200,000,010.45 between 6 May 2026 and 1 February 2027.
September Repurchases Add Up
The company’s A and B share total stands at 4,465,000,000, including treasury shares. Purchases on 31 August covered 210,000 shares at an average price of DKK 291.92, for a transaction value of DKK 61,302,771. The company purchased 215,000 shares on 1 September at DKK 293.94 per share, generating a transaction value of DKK 63,196,785. On 2 September, another 215,000 shares changed hands at an average DKK 297.42, with the transaction valued at DKK 63,945,131. The final listed transaction, on 4 September, involved 200,000 shares at DKK 300.03 per share and carried a value of DKK 60,006,094.
Programme Reaches DKK 5.22 Billion
The accumulated position before the latest transactions was 16,220,000 shares and DKK 4,907,673,815. Since 4 February 2026, Novo (NYSE: NVO) Nordisk has repurchased 32,034,179 B shares at an average price of DKK 281.63 per share. The corresponding transaction value is DKK 9,021,774,283. The company’s latest transactions therefore sit within both the broader 12-month repurchase plan and the programme launched on 6 May 2026.
Repurchases Continue Through February
The current programme allows Novo Nordisk to repurchase B shares for up to DKK 11,200,000,010.45 between 6 May 2026 and 1 February 2027. The wider plan allows purchases of up to DKK 15 billion during the 12-month period that began 4 February 2026. Novo Nordisk’s treasury shares are B shares with a nominal value of DKK 0.10 each.



Please wait processing your request...